Literature DB >> 20528115

Quality of life measures in irritable bowel syndrome.

Reuben K M Wong1, Douglas A Drossman.   

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with significant morbidity, resulting from the interaction of physiologic, psychological, social, cultural and behavioral factors. In view of this complex interaction, and in the absence of a measurable biological index of disease, health-related quality of life (HRQoL) has emerged as an ideal measure for use in clinical trials and outcome studies. This article discusses the relevance of HRQoL measurement in IBS and its definition. It then explores the research methodology in HRQoL and describes how global measures and generic HRQoL instruments have been used in IBS. Finally, the IBS-specific HRQoL measures are described in detail, with an emphasis on their development, content and validation.

Entities:  

Mesh:

Year:  2010        PMID: 20528115     DOI: 10.1586/egh.10.19

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  15 in total

1.  Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome.

Authors:  Yungwui Tjong; Siupo Ip; Lixing Lao; Harry H S Fong; Joseph J Y Sung; Brian Berman; Chuntao Che
Journal:  J Ethnopharmacol       Date:  2011-04-12       Impact factor: 4.360

2.  Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.

Authors:  Prashant Singh; Kyle Staller; Kenneth Barshop; Elaine Dai; Jennifer Newman; Sonia Yoon; Shahar Castel; Braden Kuo
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

3.  Biomechanical constitutive modeling of the gastrointestinal tissues: a systematic review.

Authors:  Bhavesh Patel; Alessio Gizzi; Javad Hashemi; Yousif Awakeem; Hans Gregersen; Ghassan Kassab
Journal:  Mater Des       Date:  2022-03-24       Impact factor: 9.417

4.  Integrated metagenomics and targeted-metabolomics analysis of the effects of phenylalanine on loperamide-induced constipation in rats.

Authors:  Chuanli Yang; Xinshu Bai; Tianjiao Hu; Xin Xue; Xiaohu Su; Xuan Zhang; Teng Wu; Mingxia Zhang; Xiaobing Shen; Xiushan Dong
Journal:  Front Microbiol       Date:  2022-09-30       Impact factor: 6.064

Review 5.  A systematic review of measurement properties of the instruments measuring health-related quality of life in patients with irritable bowel syndrome.

Authors:  Jiyeon Lee; Eun-Hyun Lee; Seung Hei Moon
Journal:  Qual Life Res       Date:  2016-09-29       Impact factor: 4.147

6.  Fear of GI symptoms has an important impact on quality of life in patients with moderate-to-severe IBS.

Authors:  Jeffrey M Lackner; Gregory D Gudleski; Chang-Xing Ma; Akriti Dewanwala; Bruce Naliboff
Journal:  Am J Gastroenterol       Date:  2014-09-16       Impact factor: 10.864

7.  Impact of Bile Acid Diarrhea in Patients With Diarrhea-Predominant Irritable Bowel Syndrome on Symptoms and Quality of Life.

Authors:  Joelle BouSaba; Wassel Sannaa; Sanna McKinzie; Priya Vijayvargiya; Victor Chedid; Xiao Jing Wang; Jessica Atieh; Ting Zheng; Justin Brandler; Ann L Taylor; Irene Busciglio; W Scott Harmsen; Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2021-12-04       Impact factor: 13.576

8.  Illness perceptions mediate the relationship between bowel symptom severity and health-related quality of life in IBS patients.

Authors:  Véronique De Gucht
Journal:  Qual Life Res       Date:  2015-02-07       Impact factor: 4.147

9.  A Measure of Suffering in relation to Anxiety and Quality of Life in IBS Patients: Preliminary Results.

Authors:  Sanda Pletikosić Tončić; Mladenka Tkalčić
Journal:  Biomed Res Int       Date:  2017-07-04       Impact factor: 3.411

10.  Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk; Odd Helge Gilja; Anja Bråthen Kristoffersen; Trygve Hausken
Journal:  Gut       Date:  2019-12-18       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.